NDA 218571 · Milestone Pharms USA
Cardamyst
Etripamil · Nasal
NovelCDER novel approval, Dec 12, 2025: To treat episodes of paroxysmal supraventricular tachycardia
Last checked: Nov 20, 2026Latest source record: Dec 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Dec 12, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
10
6 Phase 3, 2 recruiting
FAERS reports
11
2 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 29, 2026.
CARDAMYST is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST is a calcium channel blocker indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults ( 1 ).
Mechanism: Etripamil is an L-type calcium influx inhibitor (slow channel blocker or calcium ion antagonist). Etripamil exerts its pharmacologic effect by modulating the influx of ionic calcium across the cell membrane of the AV nodal cells as well as arterial smooth muscles and contractile myocardial cells. By interrupting reentry at the AV node, etripamil can restore sinus rhythm in patients with PSVT.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- CARDAMYST · ETRIPAMIL 70MG · SPRAY, NASAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Etripamil" as an intervention, any sponsor and status, largest first.
- Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303Pivotal-lookingCompleted
Milestone Pharmaceuticals Inc.Academic, hospital or other
NCT04072835 · 1,116 participants · Start Sep 23, 2019 · Primary completion Jan 26, 2023
Drug: Etripamil NS · For: Paroxysmal Supraventricular Tachycardia
Sites: Gilbert, Arizona; Fremont, California; Stanford, California · 124 sites in all
- Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).Pivotal-lookingTerminated
Milestone Pharmaceuticals Inc.Academic, hospital or other
NCT03464019 · 1,097 participants · Start Jun 18, 2018 · Primary completion Jan 20, 2023
Drug: Etripamil; Placebo and 1 more · For: Paroxysmal Supraventricular Tachycardia
Sites: Phoenix, Arizona; Little Rock, Arkansas; Cerritos, California · 161 sites in all
- ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3Pivotal-lookingRecruiting
Milestone Pharmaceuticals Inc.Academic, hospital or other
NCT06716021 · 750 participants (planned) · Start Aug 20, 2026 · Primary completion Dec 2028
Drug: Placebo; Etripamil · For: Atrial Fibrillation
Sites: Vista, California; West Hills, California; Littleton, Colorado · 23 sites in all
- Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular TachycardiaPivotal-lookingCompleted
Corxel PharmaceuticalsIndustry
NCT05410860 · 500 participants · Start Jun 30, 2022 · Primary completion Aug 2, 2024
Drug: Etripamil NS 70 mg; Placebo · For: Tachycardia, Supraventricular; Paroxysmal Supraventricular Tachycardia
Sites: Baotou, China; Beijing, China; Bengbu, China · 53 sites in all
- Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus RhythmPivotal-lookingCompleted
Milestone Pharmaceuticals Inc.Academic, hospital or other
NCT02296190 · 199 participants · Start Mar 27, 2015 · Primary completion Dec 2016
Drug: Etripamil; Placebo · For: Paroxysmal Supraventricular Tachycardia (PSVT)
Sites: Phoenix, Arizona; Sacramento, California; Littleton, Colorado · 30 sites in all
- Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302Pivotal-lookingTerminated
Milestone Pharmaceuticals Inc.Academic, hospital or other
NCT03635996 · 169 participants · Start Dec 10, 2018 · Primary completion Nov 13, 2020
Drug: Etripamil NS 70 mg · For: Paroxysmal Supraventricular Tachycardia
Sites: Phoenix, Arizona; Little Rock, Arkansas; Los Alamitos, California · 34 sites in all
- Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular TachycardiaPivotal-lookingCompleted
Milestone Pharmaceuticals Inc.Academic, hospital or other
NCT04952610 · 130 participants · Start Dec 13, 2021 · Primary completion Apr 10, 2026
Drug: Etripamil NS 70 mg · For: Paroxysmal Supraventricular Tachycardia
Sites: Little Rock, Arkansas; Vista, California; West Hills, California · 23 sites in all
Milestone Pharmaceuticals Inc.Academic, hospital or other
NCT04467905 · 69 participants · Start Nov 19, 2020 · Primary completion Aug 3, 2023
Drug: Etripamil; Placebo · For: Atrial Fibrillation
Sites: Halifax, Canada; Hamilton, Canada; Newmarket, Canada · 18 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nasal discomfort4
- oropharyngeal pain3
- drug ineffective2
- hypertension2
- hypotension2
- nasal dryness2
- rhinalgia2
- wrong technique in product usage process2
- contraindicated product prescribed1
- drug effect less than expected1
- dysgeusia1
- epistaxis1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 11 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results From the NODE-303 Open-Label Study.
Ip JE, Coutu B, Ip JH, et al. · J Cardiovasc Electrophysiol 2025 · Clinical Trial, Phase III, Multicenter Study
- Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial.
Stambler BS, Camm AJ, Alings M, et al. · Lancet 2023 · Randomized Controlled Trial, Multicenter Study
- Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm.
Stambler BS, Dorian P, Sager PT, et al. · J Am Coll Cardiol 2018 · Clinical Trial, Phase II, Multicenter Study
- The Efficacy and Safety of Etripamil Nasal Spray for Acute Paroxysmal Supraventricular Tachycardia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Abuelazm M, Kambalapalli S, Saleh O, et al. · Am J Cardiovasc Drugs 2023 · Meta-Analysis, Systematic Review
- Pharmacokinetics and Pharmacodynamics of Etripamil, an Intranasally Administered, Fast-Acting, Nondihydropyridine Calcium Channel Blocker.
Ip JE, Wight D, Yue CS, et al. · Clin Pharmacol Drug Dev 2024 · Randomized Controlled Trial, Clinical Trial, Phase I
- Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201).
Camm AJ, Piccini JP, Alings M, et al. · Circ Arrhythm Electrophysiol 2023 · Randomized Controlled Trial, Multicenter Study
Sponsor: Milestone Pharms USA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.